Dissecting the function of cytochrome p450

British Journal of Clinical Pharmacology

Volumn 42, Issue 1, 1996, Pages 81-89

  Boobis, Alan R ^a   Edwards, Robert J ^a   Adams, Delyth A ^a   Davies, Donald S ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Antibodies; Drug metabolism; Human liver; Immunological analysis; Inhibition; P450; Peptides; Protein structure

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY;

AMINO ACID SEQUENCE; CONFERENCE PAPER; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME STRUCTURE; GENETIC POLYMORPHISM; HAMSTER; HUMAN; IMMUNOBLOTTING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPECIES DIFFERENCE;

EID: 0029948998     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.37912.x     Document Type: Conference Paper

References (67)

1. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 1964; 239: 2370-2378.
2. Davies DS, Thorgeirsson SS, Breckenridge A, Orme M. Interindividual differences in rates of drug oxidation in man. Drug Metab Dispos 1973; 1: 411-417.
3. Davies DS, Thorgeirsson SS. Mechanism of hepatic drug oxidation and its relationship to individual differences in rates of oxidation in man. Ann NY Acad Sci 1971; 179: 411-420.
4. Fraser HS, Mucklow JC, Bulpitt CJ, Kahn C, Mould G, Dollery CT. Environmental factors affecting antipyrine metabolism in London factory and office workers. Br J Clin Pharmacol 1979; 7: 237-243.
5. Fraser HS, Mucklow JC, Bulpitt CJ, Khan C, Mould G, Dollery CT. Environmental effects on antipyrine half-life in man. Clin Pharmacol Ther 1977; 22: 799-808.
6. Fraser HS, Bulpitt CJ, Kahn C, Mould G, Mucklow JC, Dollery CT. Factors affecting antipyrine metabolism in West African villagers. Clin Pharmacol Ther 1976; 20: 369-376.
7. Brodie MJ, Boobis AR, Toverud EL, et al. Drug metabolism in white vegetarians. Br J Clin Pharmacol 1980; 9: 523-525.
8. Desai NK, Sheth UK, Mucklow JC, et al. Antipyrine clearance in Indian villagers. Br J Clin Pharmacol 1980; 9: 387-394.
9. Mucklow JC, Rawlins MD, Brodie MJ, Boobis AR, Dollery CT. Drug oxidation in Asian vegetarians. Lancet 1980; ii: 151
10. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; ii: 584-586.
11. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979; 16: 183-187.
12. Spannbrucker N, Eichelbaum M, Steinke B, Dengler HJ. A human genetic defect in the metabolism of sparteine. Verh Dtsch Ges Inn Med 1978; 1125-1127.
13. Davies DS, Kahn GC, Murray S, Brodie MJ, Boobis AR. Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver. Br J Clin Pharmacol 1981; 11: 89-91.
14. Gonzalez FJ, Skoda RC, Kimura S, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988; 331: 442-446.
15. Archakov AI, Degtyarenko KN. Structural classification of the P450 superfamily based on consensus sequence comparison. Biochem Mol Biol Int 1993; 31: 1071-1080.
16. Gonzalez FJ. Human cytochromes P450: problems and prospects. Trends Pharmacol Sci 1992; 13: 346-352.
17. Nelson DR, Kamataki T, Waxman DJ, et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993; 12: 1-51.
18. Bossart J, Pearson B. Commercialization of gene therapy - the evolution of licensing and rights issues. Trends Biotechnol 1995; 13: 290-294.
19. DiMasi JA. Success rates for new drugs entering clinical testing in the United States. Clin Pharmacol Ther 1995; 58: 1-14.
20. Drews J. Intent and coincidence in pharmaceutical discovery. The impact of biotechnology. Arzneimittelforschung 1995; 45: 934-939.
21. Kleinberg ML, Wanke LA. New approaches and technologies in drug design and discovery. Am J Health Syst Pharm 1995; 52: 1323-1336.
22. MacInnes R, Lumley CE, Walker SR. New chemical entity output of the international pharmaceutical industry from 1970 to 1992. Clin Pharmacol Ther 1994; 56: 339-349.
23. Smith DA. Design of drugs through a consideration of drug metabolism and pharmacokinetics. Eur J Drug Metab Pharmacokinet 1994; 19: 193-199.
24. Miller JA. Recent studies on the metabolic activation of chemical carcinogens. Cancer Res 1994; 54: 1879s-1881s.
25. Shubik P. Chemical carcinogens and human cancer. Cancer Lett 1995; 93: 3-7.
26. Waller RE. 60 years of chemical carcinogens: Sir Ernest Kennaway in retirement. J R Soc Med 1994; 87: 96-97.
27. Caporaso N, Goldstein A. Cancer genes: single and susceptibility: exposing the difference. Pharmacogenetics 1995; 5: 59-63.
28. Gonzalez FJ, Gelboin HV. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 1994; 26: 165-183.
29. Rannug A, Alexandrie AK, Persson I, Ingelman Sundberg M. Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: regulation and toxicological significance. J Occup Environ Med 1995; 37: 25-36.
30. Wolf CR, Smith CA, Forman D. Metabolic polymorphisms in carcinogen metabolising enzymes and cancer susceptibility. Br Med Bull 1994; 50: 718-731.
31. Edwards RJ, Murray BP, Murray S, et al. Contribution of CYP1A1 and CYP1A2 to the activation of heterocyclic amines in monkeys and human. Carcinogenesis 1994; 15: 829-836.
32. Boobis AR, Brodie MJ, Kahn GC, Fletcher DR, Saunders JH, Davies DS. Monooxygenase activity of human liver in microsomal fractions of needle biopsy specimens. Br J Clin Pharmacol 1980; 9: 11-19.
33. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497.
34. Boobis AR, Slade MB, Stern C, Lewis KM, Davies DS. Monoclonal antibodies to rabbit liver cytochrome P-448. Life Sci 1981; 29: 1443-1448.
35. Boobis AR, Davies DS, McQuade J, Sesardic D. Specificity of isozymes of cytochrome P-450 determined by inhibitory monoclonal antibodies. Br J Pharmacol 1985; 86: 511P.
36. Boobis AR, McQuade J, Sesardic D, et al. A monoclonal antibody raised to rat liver cytochrome P-448 (form C) which recognises an epitope common to many other forms of cytochrome P-450. Biochem Pharmacol 1985; 34: 1671-1681.
37. Sesardic D, Boobis AR, McQuade J, et al. Inter-relatedness of some isoenzymes of cytochrome P-450 from rat, rabbit and human, determined with monoclonal antibodies. Biochem J 1986; 236: 569-577.
38. Sesardic D, Cole KJ, Edwards RJ, et al. The inducibility and catalytic activity of cytochromes P450c (P450IA1) and P450d (P450IA2) in rat tissues. Biochem Pharmacol 1990; 39: 499-506.
39. Edwards RJ, Sesardic D, Murray BP, Singleton AM, Davies DS, Boobis AR. Identification of the epitope of a monoclonal antibody which binds to several cytochromes P450 in the CYP1A subfamily. Biochem Pharmacol 1992; 43: 1737-1746.
40. Sagami I, Kikuchi H, Ikawa S, Watanabe M. Characterization of hamster CYP1A1 gene: inducible expression and negative regulation. J Biochem Tokyo 1994; 116: 801-810.
41. Edwards RJ, Murray BP, Murray S, Singleton AM, Davies DS, Boobis AR. An inhibitory monoclonal anti-protein antibody and an anti-peptide antibody share an epitope on rat cytochrome P-450 enzymes CYP1A1 and CYP1A2. Biochim Biophys Acta 1993; 1161: 38-46.
42. Poulos TL, Finzel BC, Howard AJ. High-resolution crystal structure of cytochrome P450cam. J Mol Biol 1987; 195: 687-700.
43. Edwards RJ, Murray BP, Boobis AR, Davies DS. Identification and location of alpha-helices in mammalian cytochromes P450. Biochemistry 1989; 28: 3762-3770.
44. Edwards RJ, Murray BP, Boobis AR. Antipeptide antibodies in studies of cytochromes P450IA. Methods Enzymol 1991; 206: 220-233.
45. Edwards RJ, Singleton AM, Sesardic D, Boobis AR, Davies DS. Antibodies to a synthetic peptide that react specifically with a common surface region on two hydrocarbon-inducible isoenzymes of cytochrome P-450 in the rat. Biochem Pharmacol 1988; 37: 3735-3741.
46. Edwards RJ, Singleton AM, Murray BP, Davies DS, Boobis AR. Short synthetic peptides exploited for reliable and specific targeting of antibodies to the C-termini of cytochrome P450 enzymes. Biochem Pharmacol 1995; 49: 39-47.
47. Edwards RJ, Singleton AM, Murray BP, Murray S, Boobis AR, Davies DS. Identification of a functionally conserved surface region of rat cytochromes P450IA. Biochem J 1991; 278: 749-757.
48. Edwards RJ, Murray BP, Singleton AM, Boobis AR. Orientation of cytochromes P450 in the endoplasmic reticulum. Biochemistry 1991; 30: 71-76.
49. Sesardic D, Boobis AR, Murray BP, et al. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmacol 1990; 29: 651-663.
50. Alvan G, Bechtel P, Iselius L, Gundert Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990; 39: 533-537.
51. Fernandez Salguero P, Hoffman SM, Cholerton S, et al. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet 1995; 57: 651-660.
52. Wrighton SA, Brian WR, Sari MA, et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990; 38: 207-213.
53. Mimura M, Baba T, Yamazaki H, et al. Characterization of cytochrome P-450 2B6 in human liver microsomes. Drug Metab Dispos 1993; 21: 1048-1056.
54. Hakkola J, Pasanen M, Hukkanen J, et al. Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta.. Biochem Pharmacol 1996; 51: 403-411.
55. Gradin K, Wilhelmsson A, Poellinger L, Berghard A. Nonresponsiveness of normal human fibroblasts to dioxin correlates with the presence of a constitutive xenobiotic response element-binding factor. J Biol Chem 1993; 268: 4061-4068.
56. Szklarz GD, Ornstein RL, Halpert JR. Application of 3-dimensional homology modeling of cytochrome P450 2B1 for interpretation of site-directed mutagenesis results. J Biomol Struct Dyn 1994; 12: 61-78.
57. Edwards RJ, Singleton AM, Murray BP, et al. An anti-peptide antibody targeted to a specific region of rat cytochrome P-450IA2 inhibits enzyme activity. Biochem J 1990; 266: 497-504.
58. Parkinson A, Thomas PE, Ryan DE, et al. Mechanism of inactivation of rat liver microsomal cytochrome P-450c by 2-bromo-4'-nitroacetophenone. J Biol Chem 1986; 261: 11487-11495.
59. Manns MP, Johnson EF, Griffin KJ, Tan EM, Sullivan KF. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J Clin Invest 1989; 83: 1066-1072.
60. Zanger UM, Hauri HP, Loeper J, Homberg JC, Meyer UA. Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. Proc Natl Acad Sci USA 1988; 85: 8256-8260.
61. Gueguen M, Boniface O, Bernard O, Clerc F, Cartwright T, Alvarez F. Identification of the main epitope on human cytochrome P450 IID6 recognized by anti-liver kidney microsome antibody. J Autoimmun 1991; 4: 607-615.
62. Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991; 88: 1370-1378.
63. Murray BP, Edwards RJ, Davies DS, Boobis AR. Conservation of a functionally important surface region between two families of the cytochrome P-450 superfamily. Biochem J 1993; 292: 309-310.
64. Sesardic D, Boobis AR, Edwards RJ, Davies DS. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 1988; 26: 363-372.
65. Deprez E, Gerber NC, Di Primo C, Douzou P, Sligar SG, Hui Bon Hoa G. Electrostatic control of the substrate access channel in cytochrome P-450cam. Biochemistry 1994; 33: 14464-14468.
66. Miles JS, Munro AW, Rospendowski BN, Smith WE, McKnight J, Thomson AJ. Domains of the catalytically self-sufficient cytochrome P-450 BM-3. Genetic construction, overexpression, purification and spectroscopic characterization. Biochem J 1992; 288: 503-509.
67. Shen S, Strobel HW. Role of lysine and arginine residues of cytochrome P450 in the interaction between cytochrome P4502B1 and NADPH-cytochrome P450 reductase. Arch Biochem Biophys 1993; 304: 257-265.